398 related articles for article (PubMed ID: 16236745)
21. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
[TBL] [Abstract][Full Text] [Related]
22. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
Ferretti G; Fabi A; Felici A; Papaldo P
J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
[No Abstract] [Full Text] [Related]
23. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
24. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab treatment in breast cancer.
Montemurro F; Valabrega G; Aglietta M
N Engl J Med; 2006 May; 354(20):2186; author reply 2186. PubMed ID: 16707759
[No Abstract] [Full Text] [Related]
26. Managing trastuzumab-resistant breast cancer.
Krop I
Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
[No Abstract] [Full Text] [Related]
27. Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.
Danese MD; Lalla D; Brammer M; Doan Q; Knopf K
Cancer; 2010 Dec; 116(24):5575-83. PubMed ID: 20734398
[TBL] [Abstract][Full Text] [Related]
28. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
Kulkarni S; Hicks DG
Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.
Rodrigues MJ; Wassermann J; Albiges L; Brain E; Delaloge S; Stevens D; Guinebretière JM; Mathieu MC; Kirova Y; Guillot E; Vincent-Salomon A; Cottu PH
J Clin Oncol; 2010 Oct; 28(28):e541-2. PubMed ID: 20660834
[No Abstract] [Full Text] [Related]
30. Continuing trastuzumab beyond progression.
Jahanzeb M
J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
[No Abstract] [Full Text] [Related]
31. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
Heinzl S
Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
[No Abstract] [Full Text] [Related]
32. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab beyond disease progression: case closed?
Valabrega G; Aglietta M; Montemurro F
J Clin Oncol; 2009 Sep; 27(27):e121-2; author reply e124-5. PubMed ID: 19687323
[No Abstract] [Full Text] [Related]
34. [Adjuvant chemotherapy for breast cancer and targeted therapies].
Dufresne A; Bachelot T; Blay JY
Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
[No Abstract] [Full Text] [Related]
35. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
36. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
38. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
Mahtani RL; Vogel CL
J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
[No Abstract] [Full Text] [Related]
39. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
40. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
Liao C; Yin F; Huang P; Cao Y; Gao F
Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
